Clinical trials: Viremia
HIV, Acute HIV Infection
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).
- Trial name
- PHI-05 (NCT02384395)
- Testing
- Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
Cytomegalovirus Viraemia
Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients
This study will evaluate whether a test for Cytomegalovirus (CMV) specific cell-mediated immunity can be used to determine whether patients who complete a course of therapy for CMV viremia need secondary antiviral prophylaxis.
- Trial name
- Q-CMV (NCT02370758)
- Testing
- Valganciclovir or Ganciclovir
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University Health Network, Toronto
HIV -1 Infection, Antiretroviral Therapy
Impacts of HIV Treatment Regimens on Archived Drug Resistance
The study aims to determine the prevalence of drug resistance mutation (DRM) in virally suppressed HIV infection, and the impacts of regimen change and the presence of low level viremia.
- Conditions
- HIV -1 Infection, Antiretroviral Therapy, Drug Resistance, Microbial
- Trial name
- NCT07643948
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Chinese University of Hong Kong
Cytomegalovirus Infections, CMV
Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV
To evaluate the Quantiferon-CMV test ability to predict occurrence of cytomegalovirus (CMV) disease o treated infection after kidney transplantation.
- Conditions
- Cytomegalovirus Infections, CMV, Kidney Transplant Infection
- Trial name
- NCT03858907
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- University of Sao Paulo General Hospital
Hiv
The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY
Antiretroviral therapy or ART blocks HIV replication reducing plasma viral loads to undetectable levels but has no effect on persistently infected cells in the body, called the virus reservoir.
- Trial name
- "TACKITON (NCT06823596)
- Testing
- Efavirenz 600mg
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- University of Toronto
HIV Infections
A Multicenter, Exploratory Study to Evaluate the Effects of Antiretroviral Cessation on Plasma Associated HIV-1 RNA
To evaluate viral load in the blood stream of HIV-infected patients during a 28-day washout following cessation of long-term zidovudine ( AZT ) therapy.
- Trial name
- NCT00000840
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Predictors of Time to Viremia With an Analytic Treatment Interruption
This is a two-center study of 30 HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.
- Trial name
- NCT03033017
- Testing
- Blood Testing
- Where
- 2 sites in United States
- Sponsor
- University of Minnesota
Disease Due to BK Polyomavirus, Transplantation Infection
Induction Related BK Viremia in Renal Transplant Patients
The increase immunosuppression in our transplant population has led to an unacceptable rate of patients at risk for BK virus nephropathy.
- Conditions
- Disease Due to BK Polyomavirus, Transplantation Infection, Disorder Related to Transplantation
- Trial name
- BK (NCT00610961)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
CMV Infection, CMV Viremia
Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
This is a single-center, non-interventional, retrospective study of data, at the level of the individual without identification, extracted from medical records of adult patients undergoing a kidney transplant procedure after 1st…
- Trial name
- NCT06263218
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Hospital do Rim e Hipertensão
HIV
Emtricitabine/Tenofovir Alafenamide as Salvage ART
Background: HIV attacks the immune system. Antiretroviral therapy (ART) is a combination of drugs used for treating HIV infection. For some people, ART drugs stop working against their HIV.
- Trial name
- NCT02556333
- Testing
- FTC/TAF
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Viremia, Bacteremia
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are: 1.
- Conditions
- Viremia, Bacteremia, Acute Rejection of Renal Transplant
- Trial name
- NCT05799716
- Testing
- IVIG
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
Cytomegalovirus Viraemia
Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients
The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ…
- Trial name
- QFT-CMV (NCT02784756)
- Testing
- Quantiferon-CMV assay
- Where
- 6 sites in Canada, Spain
- Volunteers
- 134 people
- Sponsor
- University Health Network, Toronto
BK Virus Infection
Ciprofloxacin for Prevention of BK Infection
BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppressive agents used to lower…
- Trial name
- NCT01789203
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Methodist Hospital Research Institute
HIV Seropositivity
Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia
Prospective, open-label, single arm, non-randomized, proof-of-concept study. Eligible patients will sign a written informed consent and will be followed-up at screening, baseline (ART interruption) and at 1, 2, 3, 4, 6, 8, 10…
- Trial name
- APACHE (NCT03198325)
- Testing
- Stop of ART
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- IRCCS San Raffaele
Acute HIV Infection, HIV Infections
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
Purpose: This is a pilot study to evaluate HIV viremia and persistence in acutely HIV infected antiretroviral naïve patients treated with Darunavir/ritonavir and Etravirine Participants: 20 participants, age 18 and older, HIV…
- Trial name
- NCT00855413
- Testing
- Darunavir, Ritonavir, Etravirine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Human Immunodeficiency Virus, Treatment Adherence
Data Science and Qualitative Research for Decision Support in the HIV Care Cascade
The goal of this study is to determine whether clinical prediction algorithms derived using statistical machine learning methods can be used to improve patient outcomes in large HIV care programs in sub-Saharan Africa and…
- Conditions
- Human Immunodeficiency Virus, Treatment Adherence, Treatment Compliance, Patient No Show
- Trial name
- CASCADE (NCT06604663)
- Testing
- Activation of the CDSS system
- Where
- Kenya
- Volunteers
- 80,000 people
- Sponsor
- Brown University
Hepatitis B, Chronic
Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy
This observational long-term follow-up study will evaluate demographic, clinical, histological, biochemical, and virological parameters of patients with chronic hepatitis B and low viremia who do not require antiviral therapy…
- Trial name
- NCT01090531
- Where
- 6 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Chronic HBV Infection
A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia
This is a multicenter, randomized, controlled Phase IIa study of HH-003 to evaluate the antiviral activity and safety in nucleos(t)ide analogues-treated chronic hepatitis B subjects with low-level viremia.
- Trial name
- NCT05734807
- Testing
- Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs), HH-003 and NrtIs, HH-003, NrtIs and PEG-IFN-α
- Where
- 8 sites in China
- Volunteers
- 74 people
- Sponsor
- Huahui Health
HIV Vaccine
Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals
The goal of this interventional study is to validate the strategy of adjuvant therapy with dendritic cells in HIV infection in chronically infected individuals.
- Trial name
- NCT05786937
- Testing
- Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides, Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides, Commercial ringer´s lactate solution
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo General Hospital
Congenital Heart Disease, Viremia
Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes
Beyond EV-B, there are clinical observations to implicate other viruses in birth defects, including CHD. Since the Rubella epidemic of 1960s', however, viruses have received little attention and certainly no comprehensive study…
- Conditions
- Congenital Heart Disease, Viremia, Virus Diseases, Enterovirus
- Trial name
- CHARMED (NCT04769167)
- Testing
- Stool and Blood Specimen Collection, Follow-up Medical Record Review
- Where
- 2 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine